Prospective multicentre study of experience in real-world clinical practice in monitoring reported outcome measures (PROMs) of patient with a diagnosis of psoriatic and/or spondyloarthritis and initiating treatment with secukinumab.

Autor: Garrido JJL; Hospital General Universitario de Valencia, Valencia, Spain. Electronic address: jjlerma@comv.es., Pérez AG; Hospital de Sagunto, Sagunto, Valencia, Spain., Torres AP; Hospital de Lliria, Llíria, Valencia, Spain., Cid AR; Hospital General Universitario de Valencia, Valencia, Spain., Almela CM; Hospital General Universitario de Valencia, Valencia, Spain., Cubillo MDP; Hospital General Universitario de Valencia, Valencia, Spain., Fernández CC; Hospital General Universitario de Valencia, Valencia, Spain., Trull IB; Hospital General Universitario de Valencia, Valencia, Spain., Carmona L; Instituto de Salud Musculoesquelética, Madrid, Spain., Catalá JC; Hospital General Universitario de Valencia, Valencia, Spain.
Jazyk: angličtina
Zdroj: Reumatologia clinica [Reumatol Clin (Engl Ed)] 2022 Jan; Vol. 18 (1), pp. 25-29. Date of Electronic Publication: 2021 Apr 07.
DOI: 10.1016/j.reumae.2020.07.010
Abstrakt: Objective: To analyse the effect of secukinumab on self-reported variables of patients diagnosed with psoriatic arthritis and/or ankylosing spondylitis in relation to their health status, pain, fatigue, sleep and quality of life.
Methods: A six-month, observational, longitudinal, prospective, multicentre study was conducted with 39 patients who initiated treatment with secukinumab as therapy for psoriatic arthritis and/or spondylitis. The main variables were changes in patient-reported measures and they were evaluated by means of the questionnaires: FACIT-fatigue, Insomnia Severity Index, EuroQol-3L-5D and PsAQoL. In addition, depending on the type of disease (peripheral psoriasis or spondyloarthritis) the DAS28 with ESR or the BASDAI were calculated, respectively.
Results: Levels of fatigue, moderate and severe insomnia significantly reduced after 6 months of treatment with secukinumab. At the same time, patient-reported quality of life increased significantly (P = .006). Data on pain and discomfort also show significant improvement after the treatment.
Conclusions: Patients with psoriatic arthritis and/or ankylosing spondylitis who start treatment with secukinumab show improvement at 6 months in all effect sizes of the treatment, particularly in sleep, fatigue and quality of life. Furthermore, patient-reported outcome measures are of additional clinical value and allow more accurate and closer assessment of their real status of health and well-being.
(Copyright © 2020 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: